OM:MCOV BHealthcare
Does Medicover’s (OM:MCOV B) MRD Assay Data Shift the Innovation Narrative in Cancer Diagnostics?
Medicover recently announced additional results from the ongoing DART clinical study at Oslo University Hospital, highlighting the strength of its hybrid capture-based, tumour-agnostic MRD assay for minimal residual disease detection in unresectable stage III non-small cell lung cancer.
The study’s findings showed that ctDNA detection could predict disease progression up to 7.4 months earlier than imaging, earning recognition with a Best Poster award at the European Society for Medical...